Clinical Trial Update: Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 study at Virginia Commonwealth University evaluating reduced-dose chemotherapy plus anti-PD-1 therapy as first-line treatment for older, vulnerable pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Virginia Commonwealth University | Conditions: Non-Small Cell Lung Cancer, NSCLC | Phase 2 | Status: RECRUITING